Filtered By:
Cancer: Acute Leukemia
Education: Study

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 50 results found since Jan 2013.

Role of beta‐defensin 2 and interleukin‐4 receptor as stroke outcome biomarkers
Abstract Acute ischemic stroke is a complex disease with huge interindividual evolution variability that makes challenging the prediction of an adverse outcome. Our aim was to study the association of bloodstream signatures to early neurological outcome after stroke, by combining a subpooling of samples strategy with protein array discovery approach. Plasma samples from 36 acute stroke patients (< 4.5 h from onset) were equally pooled within outcome groups: worsening, stability, and improvement (n = 3 pools of four patients each, for each outcome group). These nine pools were screened using a 177 antibodies library,...
Source: Journal of Neurochemistry - February 11, 2014 Category: Neurology Authors: Teresa García‐Berrocoso, Dolors Giralt, Alejandro Bustamante, Victor Llombart, Marta Rubiera, Anna Penalba, Cristina Boada, Marc Espadaler, Carlos Molina, Joan Montaner Tags: Original Article Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Conclusions Patients with AML have an elevated risk of CVA compared to all inpatients and mortality in this population is high. Better characterization of risk factors of stroke in this vulnerable population is still needed. Teaser Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke i...
Source: Clinical Lymphoma Myeloma and Leukemia - September 21, 2017 Category: Cancer & Oncology Source Type: research

Targeting antioxidant enzyme expression as a therapeutic strategy for ischemic stroke
Publication date: Available online 30 December 2016 Source:Neurochemistry International Author(s): Stephanie M. Davis, Keith R. Pennypacker During ischemic stroke, neurons and glia are subjected to damage during the acute and neuroinflammatory phases of injury. Production of reactive oxygen species (ROS) from calcium dysregulation in neural cells and the invasion of activated immune cells are responsible for stroke-induced neurodegeneration. Scientists have failed thus far to identify antioxidant-based drugs that can enhance neural cell survival and improve recovery after stroke. However, several groups have demonstrated ...
Source: Neurochemistry International - December 30, 2016 Category: Neuroscience Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke included UTI, hypernatremia and acute renal failure.
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Christopher Del Prete, Taeha Kim, Frederick Lansigan, Joseph Shatzel, Harley Friedman Source Type: research

A Unique Presentation of Pediatric Stroke Attributed to Intrathecal Methotrexate (P3.309)
CONCLUSIONS:This is a rare case of ischemic watershed infarcts with diffuse reversible cerebral vasospasm, after intrathecal methotrexate. This highlights the need for further research into the pathogenesis of methotrexate neurotoxicity including endothelial damage.Study Supported by:Disclosure: Dr. Ilyas has nothing to disclose. Dr. Williams has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ilyas, M., Williams, M. Tags: Neurologic Complications of Cancer Source Type: research

Effects of Slow-Stroke Back Massage on Symptom Cluster in Adult Patients With Acute Leukemia: Supportive Care in Cancer Nursing
Conclusions: Slow-stroke back massage, as a simple, noninvasive, and cost-effective approach, along with routine nursing care, can be used to improve the symptom cluster of pain, fatigue, and sleep disorders in leukemia patients. Implications for Practice: Oncology nurses can increase their knowledge regarding this symptom cluster and work to diminish the cluster components by using SSBM in adult leukemia patients.
Source: Cancer Nursing - December 6, 2016 Category: Nursing Tags: Articles Source Type: research

Neuregulin-1/PI3K signaling effects on oligodendrocyte proliferation, remyelination and behaviors deficit in a male mouse model of ischemic stroke
In this study, we investigated the effect of neuregulin-1 (NRG1) on demyelination and neurological function in an ischemic stroke model, and further explored its neuroprotective mechanisms. Adult male ICR mice underwent photothrombotic ischemia surgery and were injected with NRG1 beginning 30 min after ischemia. Cylinder and grid walking tests were performed to evaluate the forepaw function. In addition, the effect of NRG1 on neuronal damage/death (Cresyl violet, CV), neuronal nuclei (NeuN), nestin, doublecortin (DCX), myelin basic protein (MBP), non-phosphorylated neurofilaments (SMI-32), adenomatous polyposis coli (APC),...
Source: Experimental Neurology - January 23, 2023 Category: Neurology Authors: Mai Yin Cui Yan Qiong Fu Zhuo Li Li Yu Zheng Yi Yu Chan Zhang Yun Qi Zhang Bing Rui Gao Wu Yue Chen Yun-Lyul Lee Moo-Ho Won Min Liao Yong Jian Bai Hui Chen Source Type: research

Effects of Neurotrophic Factors in Glial Cells in the Central Nervous System: Expression and Properties in Neurodegeneration and Injury
Conclusion and Future Aspects This review summarizes available NTF expression data, compiles existing evidence on the effects of glial NTF signaling in healthy conditions and in disease models (Figure 1), and highlights the importance of this topic for future studies. The relationship between NTFs and glia is crucial for both the developing and adult brain. While some of these factors, such as NT-3 and CNTF, have highly potent effects on gliogenesis, others like BDNF and GDNF, are important for glia-mediated synapse formation. Neurotrophic factors play significant roles during neurodegenerative disorders. In many cases, ...
Source: Frontiers in Physiology - April 25, 2019 Category: Physiology Source Type: research

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
CONCLUSIONS: Approximately 2 out of 10 hematological cancer patients experienced MI, ischemic stroke, VTE, or bleeding requiring hospital contact within 10 years. The hematological cancer cohort had higher hazards of MI, ischemic stroke, VTE, and bleeding requiring hospital contact than a general population comparison cohort. This article is protected by copyright. All rights reserved. PMID: 31054195 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2019 Category: Hematology Authors: Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, Rørth M, Sørensen HT Tags: J Thromb Haemost Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Inflammatory Claims About Inflammation
We all appreciate the elegance of simple solutions to complex problems. But we know too that simplicity can often masquerade as truth, hiding a more nuanced reality. Such is the case with inflammation, where pseudoscience, exaggerated claims, false promises, and dangerous oversimplification have dominated for too long. Here is a typical missive: "Inflammation controls our lives. Have you or a loved one dealt with pain, obesity, ADD/ADHD, peripheral neuropathy, diabetes, heart disease, stroke, migraines, thyroid issues, dental issues, or cancer? If you answered yes to any of these disorders you are dealing with inflammatio...
Source: Science - The Huffington Post - May 29, 2015 Category: Science Source Type: news

Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations
Conclusion. This case series revealed large phenotypic variability in patients with ADA2 deficiency though they were homozygous for the same R169Q mutation in CECR1. Disease modifiers, including epigenetic and environmental factors, thus seem important in determining the phenotype. Furthermore, haematopoietic cell transplantation appears promising for those patients with a severe clinical phenotype.
Source: Rheumatology - April 13, 2016 Category: Rheumatology Authors: Van Montfrans, J. M., Hartman, E. A. R., Braun, K. P. J., Hennekam, E. A. M., Hak, E. A., Nederkoorn, P. J., Westendorp, W. F., Bredius, R. G. M., Kollen, W. J. W., Schölvinck, E. H., Legger, G. E., Meyts, I., Liston, A., Lichtenbelt, K. D., Gilta Tags: Immunogenetics CLINICAL SCIENCE Source Type: research